Table 1.

Effect of 10 years' treatment with chlorpropamide, glibenclamide, or insulin on patients with newly diagnosed type 2 diabetes

	Any diabetes related end points* (%)	Microvascular disease (%)	Individual macrovascular disease end points†	Median haemoglobin A1c (%)
Dietary advice plus chlorpropamide, glibenclamide, or insulin	35.3	8.2	No significant difference between the groups for any of the individual end points‡	Chlorpropamide 6.7; glibenclamide 7.2; insulin 7.1
Dietary advice only	38.5	10.6		7.9
Relative risk reduction	8.2	22.6		Significantly lower for all drugs compared with dietary advice
Absolute risk reduction	3.2§	2.4
No needed to treat for 10 years to prevent one event	31	42

^*Sudden death, death from hyperglycaemia or hypoglycaemia, fatal or non-fatal myocardial infarction, angina, heart failure, stroke, renal failure, amputation, vitreous haemorrhage, retinal photocoagulation, blindness in one eye, cataract extraction. 

^†Deaths related to diabetes, all cause mortality, myocardial infarction, stroke, blindness, renal failure, or neurological events. 

^‡P value for myocardial infarctions was 0.052 (dietary advice plus drug treatment 14.2% v dietary advice 16.3%). However, because the study was continued after the initial results showed no differences, a breakpoint for significance of 0.05 is debatable. 

^§2.7% of this 3.2% was due to a significant reduction in retinal photocoagulation.